Direkt zum Inhalt
Merck
  • Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.

Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.

World journal of gastroenterology (2014-12-04)
Mattheus C B Wielenga, Jooske F van Lidth de Jeude, Sanne L Rosekrans, Alon D Levin, Monique Schukking, Geert R A M D'Haens, Jarom Heijmans, Marnix Jansen, Vanesa Muncan, Gijs R van den Brink
ZUSAMMENFASSUNG

To investigate if azathioprine could reduce adenoma formation in Apc(Min/+) , a mouse model of sporadic intestinal tumorigenesis. Azathioprine was administered via drinking water (estimated 6-20 mg/kg body weight per day) to Apc(Min/+) and wildtype mice. Control animals received vehicle only (DMSO) dissolved in drinking water. At 15 wk of age all mice were sacrificed and intestines of Apc(Min/+) were harvested for evaluation of polyp number. Azathioprine induced toxicity was investigated by immunohistochemical analysis on spleens. All azathioprine treated mice showed signs of drug-associated toxicity such as weight loss and development of splenic T-cell lymphomas. Although this suggests that the thiopurine concentration was clearly in the therapeutic range, it did not reduce tumor formation (48 ± 3.1 adenomas vs 59 ± 5.7 adenomas, P = 0.148). We conclude that in the absence of inflammation, azathioprine does not affect intestinal tumorigenesis.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Azathioprin, ≥98%
USP
Azathioprin, United States Pharmacopeia (USP) Reference Standard
Supelco
Azathioprin, Pharmaceutical Secondary Standard; Certified Reference Material
Azathioprin, European Pharmacopoeia (EP) Reference Standard